Capital Fund Management S.A. Sells 226,164 Shares of TransMedics Group, Inc. $TMDX

Capital Fund Management S.A. cut its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 89.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,130 shares of the company’s stock after selling 226,164 shares during the quarter. Capital Fund Management S.A. owned about 0.08% of TransMedics Group worth $3,502,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in TransMedics Group by 244.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company’s stock worth $209,448,000 after acquiring an additional 2,209,996 shares during the last quarter. Zevenbergen Capital Investments LLC bought a new position in TransMedics Group during the second quarter worth about $16,286,000. Nuveen LLC purchased a new position in shares of TransMedics Group in the first quarter worth about $5,927,000. Goldman Sachs Group Inc. raised its position in shares of TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after purchasing an additional 86,721 shares during the period. Finally, Raymond James Financial Inc. lifted its stake in shares of TransMedics Group by 135.8% during the 1st quarter. Raymond James Financial Inc. now owns 145,393 shares of the company’s stock valued at $9,782,000 after buying an additional 83,722 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on TMDX shares. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Canaccord Genuity Group boosted their price objective on TransMedics Group from $142.00 to $147.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Piper Sandler cut their target price on TransMedics Group from $145.00 to $140.00 and set an “overweight” rating for the company in a research note on Thursday, October 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th. Finally, Morgan Stanley boosted their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.00.

Insiders Place Their Bets

In other TransMedics Group news, insider Anil P. Ranganath sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the sale, the insider owned 13,955 shares in the company, valued at $2,026,545.10. This trade represents a 17.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward M. Basile sold 4,142 shares of the company’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total value of $540,323.90. Following the completion of the transaction, the director owned 2,866 shares of the company’s stock, valued at $373,869.70. The trade was a 59.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 7.00% of the company’s stock.

TransMedics Group Stock Down 5.8%

Shares of NASDAQ TMDX opened at $141.77 on Wednesday. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. The business has a 50-day moving average of $123.60 and a 200-day moving average of $122.52. The firm has a market capitalization of $4.84 billion, a price-to-earnings ratio of 57.40 and a beta of 2.06. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business had revenue of $143.82 million during the quarter, compared to analyst estimates of $145.33 million. During the same period in the previous year, the business posted $0.12 earnings per share. TransMedics Group’s revenue for the quarter was up 32.2% on a year-over-year basis. Sell-side analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.